Comparative Pharmacology
Head-to-head clinical analysis: OZILTUS versus WEGOVY HD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OZILTUS versus WEGOVY HD.
OZILTUS vs WEGOVY HD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
OZILTUS (alectinib) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK) and RET. It blocks phosphorylation and downstream signaling pathways, including STAT3 and PI3K/AKT, leading to cell cycle arrest and apoptosis in ALK-positive tumors.
WEGOVY (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and promotes satiety.
10 mg subcutaneously twice daily.
Subcutaneous injection once weekly. Initiate at 0.25 mg weekly for 4 weeks, then increase to 0.5 mg weekly for 4 weeks, then 1 mg weekly for 4 weeks, then 1.7 mg weekly for 4 weeks, then maintain at 2.4 mg weekly.
None Documented
None Documented
The terminal elimination half-life is 12-15 hours in patients with normal renal function. This supports twice-daily dosing. In patients with moderate to severe renal impairment (CrCl <30 mL/min), the half-life may be prolonged to up to 30 hours, necessitating dose adjustment.
Terminal elimination half-life approximately 165 hours (≈7 days), supporting once-weekly dosing.
OZILTUS is primarily eliminated via renal excretion (65-70% as unchanged drug) and biliary/fecal excretion (20-25% as metabolites and unchanged drug). Approximately 5% is eliminated via other routes.
Primarily renal elimination of intact peptide; ~47% excreted unchanged in urine, remainder via fecal/biliary routes (≈38%).
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist